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ABSTRACT 
       
     Nosocomial infections of multidrug-resistant Pseudomonas aeruginosa (MDRPA) are a growing 
concern in hospitalized patients in burn centers. The aim of this study was to investigate the flagellin 
profiling and antibiotic susceptibility of P. aeruginosa isolated from burn wound infections. During 8 
month study, 73 clinically P. aeruginosa isolates collected from patients hospitalized in burn ward. P. 
aeruginosa isolates were identified using standard laboratory procedures. In vitro susceptibility of 
clinical isolates of P. aeruginosa to 6 antimicrobial agents were investigated by Clinical and 
Laboratory Standards Institute (CLSI 2012) Kirby-Bauer disk diffusion assay. The frequency of 
different type of flagellin was investigated by using specific primers and by PCR method. The 
resistance rates of our isolates to 6 tested antimicrobial agents were relatively high. Imipenem has 
good activity while tobramycin and ciprofloxacin do not have any effect on P. aeruginosa isolates. Of 
73 isolates 59 (80.8%) were multidrug resistant. Twenty eight of 73 isolates were resistant to all 
antibiotics. Agarose gel electrophoresis of chromosomal DNA exhibited that 59 isolates (80.8%) of 
P. aeruginosa had type A flagellin while only 14 isolates (19.2%) had type b flagellin. Given the 
antibiotic failure treatment, it appears that alternative ways such as immunity to prevent of these 
infections could be informative. Our survey of flagellin profiling of multidrug-resistant P. aeruginosa 
isolates exhibited high frequency of type a flagellin as a major virulence factor has important role of 
immunity against infections caused by MDRPA. Functional surveillance of multidrug-resistant P. 
aeruginosa in order to prevention of resistance dissemination is necessary. 
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INTRODUCTION 
Pseudomonas aeruginosa as a nosocomial 
pathogen is the major cause of infection in burn 
centers, especially in Iran [1]. This bacterium is 
responsible for a broad spectrum disease that can 
be ranged from urinary or wound infections to 
bacteremia, endocarditis, multi-organ failure and 
death [2]. Overall, P. aeruginosa infections are 
associated with high mortality and morbidity rates 
in burn patients of developing countries. Increase 
exposure to antibiotics, indiscriminate use of them 
in the treatment of burn infections and 
development of intrinsic and acquired resistance 
mechanisms has promoted the rapid development 
of multiple resistances among P. aeruginosa 
isolates [1-3]. Nosocomial infections of 
multidrug-resistant P. aeruginosa (MDRPA) are a 
growing concern in hospitalized patients in burn 
centers [4]. Remarkable capacity of this bacterium 
in resistance to many drugs have commonly been 
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reported by several investigators in burn units. 
Widespread multi resistance among P. aeruginosa 
not only leading to increased economic cost, but 
also can with directly threatens the life of the 
patient [5, 6]. Hence immunity against infections 
caused by MDRPA is a very important. Among 
the cell surface structures of P. aeruginosa, there 
is a polar flagellum that is responsible for 
pathogenicity in mucosa, motility, attachment of 
bacteria to host cells and initial development of a 
biofilm, and activation of the host inflammatory 
response via Toll-like receptor 5 (TLR5) [7, 8]. 
Overall, P. aeruginosa isolates express a primary 
protein component of the flagellar filament that 
can be classified into two serotypes, types A (A1, 
A2) and B [9]. The A type flagellins are 
heterogeneous and have variable molecular weight 
from 45-50 kDa, while the B type flagellins are 
homogeneous and are essentially conserved in 
sequence and have an approximately molecular 
weight of 53 kDa [10]. Several studies suggesting 
that P. aeruginosa flagellin as a critical 
proinflammatory determinant appears to be 
relevant to colonization and the expression of 
proinflammatory mediators by monocytes. 
Importance of flagella as target antigens for 
vaccination in prevention of the acquisition of P. 
aeruginosa infection both in vivo and in vitro 
investigations has been well established [11]. 
Considering lack of information about flagellin 
profiling of MDRPA and need to continuous 
surveillance to prevent the further spread of 
resistant isolates and also help to physicians for 
prescription effective treatment protocol this study 
was performed. 
 
MATERIALS AND METHODS 
Bacterial strains 
    The present descriptive study was performed on 
burn cases who were hospitalized in several burn 
centers. A total of 73 clinically significant P. 
aeruginosa isolates were recovered from burn 
wound infections of hospitalized patients during 8 
month’s study. The repetitive isolates from the 
same patients were excluded. Samples were 
obtained from the depth of the lesion by swab. All 
the samples were transported to the laboratory and 
were processed immediately. All isolates were 
identified as P. aeruginosa by using standard 
microbiological tests such as; Gram stain, oxidase 
test, catalase test, argenine dihydrolase, ornithine 
decarboxylase, growth at 42°C, growth on 
cetrimide agar medium (Liofilchem, Italy), O/F 
(Oxidation-Fermentation) test and pigment 
production [12]. Samples confirmed as a P. 
aeruginosa isolates were stored in Tryptic Soy 
Broth (TSB; Merck, Germany) containing 20% 
glycerol at -70°C and were subjected to further 
investigation. 
Antimicrobial susceptibility testing 
    To evaluate antimicrobial susceptibility of 
isolates Kirby-Bauer’s Disk diffusion method was 
done according Clinical Laboratory and Standards 
Institute (CLSI; formerly National Committee for 
Clinical Laboratory Standards) criteria [13]. The 
following antimicrobial agents were used in this 
study: ceftazidime (CAZ 30µg), amikacin (AK 
30µg), gentamicin (GM 10µg), tobramycin (TN 
10µg), imipenem (IMI 10µg) and ciprofloxacin 
(CIP 5µg). Antibiotic disks used in this research 
were supplied by MAST Laboratories Ltd (Bootle, 
Merseyside, UK). P. aeruginosa ATCC 27853 was 
used as the control strain in antimicrobial 
susceptibility testing. 
Serological assay 
    Bacteria were grown for 16 to 18 hours at 37 °C 
on Tripticase Soye Agar media plates (TSA, 
Merck, Germany). For serological typing of 
flagellin, the suspension of bacteria in PBS slowly 
vortex and held at room temperature for 15 min. 
The suspension of bacteria was mixed with an 
equal volume of diluted polyclonal antibody and 
agglutination was viewed by light microscopy [14]. 
DNA extraction and PCR assay 
    Genomic DNA was extracted from bacteria on 
nutrient agar medium by using QIAamp DNA 
isolation columns (Qiagen, Hilden, Germany) 
according to the manufacturer’s procedure. The 
presence of flagellin genes was detected by PCR 
and the primers were designed as follows: Forward 
primer: 5´-TTAGCGCAGCAGGCTCAGAAC-
3´and reverse primer: 5´-
ATGGCCTTGACCGTCAACAC-3´. Primers 
were synthesized by TIB MOLBIOL 
Syntheselabor GmbH (Berlin, Germany). 
Specificity of the primer pairs was evaluated by 
using Basic local Alignment Search Tool (BLAST) 
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(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and also 
Gene Runner software (Hastings Software, 
Hastings- on-Hudson, NY, USA). The PCR 
reactions for detection flagellin genes were done a 
total volume of 25 µL. The reaction mixture 
contained 1x buffer(10 mM Tris-HCl, 50 mM KCl), 
1.5 mM MgCl2, 200M dNTPs, 0.5M of primers, 
20 pmol of each primer, 1 U of Takara Taq (Takara 
Shuzo Co., Ltd., Shiga, Japan) and 3 µL of the 
template DNA. PCR conditions for amplification of 
1200 bp and 1400bp fragments of the type a and b 
flagellin was done by thermocycler (AG 22331; 
Eppendorf, Hamburg, Germany) as follows: initial 
denaturation for 5 min at 94ºC, 35 cycles of 1min at 
94 ºC (denaturation), 1 min at 68 ºC(annealing), and 
90s at 72 ºC(extension); and a final extension cycle 
of  5 min at 72 ºC. Amplified fragments (expected 
size 1200bp for type a flagellin and 1400 bp for type 
b felagellin) were separated by 1% agarose gel 
electrophoresis at 80V for 2h. Finally, fragments 
were stained by ethidium bromide and detected 
under UV light. P. aeruginosa 8821M strain as 
control positive of type a, P. aeruginosa PAO1 
strain as control positive of type b flagellin and for 
negative control Staphylococcus aureus was used. 
Statistical analysis 
    All samples were analyzed using with SPSS 
software for Windows, version 11.0 (SPSS Inc., 
Chicago, IL). 
RESULTS 
     During the 8 months, a total of 73 samples of P. 
aeruginosa were recovered from adult male and 
female patients that were hospitalized in burn 
centers. The age range of the patients was from 12 
to 68 years with a median of 39.2. Forty nine 
hundreds (67%) were female and 24(32%) were 
male.  
The antimicrobial susceptibility test revealed that 
the rate of resistant to ceftazidime was in 72 
isolates (98.6%), ciprofloxacin in 73 (100%), 
tobramycin in 73 (100%), amikacin in 71 (97.3%), 
gentamicin in 72 (98.6%) and imipenem in 47 
(64.4%). The rates of resistance to antibiotics 
tested varied between 64% and 100 % (Table 1). 
 
 
 Table 1. Antimicrobial susceptibilities of 73 P. 
aeruginosa isolated from burn patients to 6 antimicrobial 
agents  
Antibiotics 







amikacin 71(97.3) 0(0) 2(2.7) 
gentamicin 72(98.6) 0(0) 1(1.4) 
ceftazidime 72(98.6) 0(0) 1(1.4) 
imipenem 47(64.4) 4(5.5) 22(30.1) 
tobramycin 73(100) 0(0) 0(0) 
ciprofloxacin 73(100) 0(0) 0(0) 
R: resistant; I: intermediate; S: sensitive 
 
Table 2. Different pattern of multi- drug resistance in P. aeruginosa strains isolated from burn patients 
Antibiotic resistance profiles Number of antibiotic resistant isolates 
Antibiotics 
No. 
Total number of resistant 
isolates (%) 


























TN-CIP 5 2 5(6.8) 


























Figure 1. Gel electrophoresis results of PCR product. M: 
DNA Ladder (Invitrogen™) 
(250 bp), Lane 1: Negative control, Lane 2: P. aeruginosa 
8821M (standard type a), Lane 3: P. aeruginosa PAO1 
(standard type b), Lane 4, 7: P. aeruginosa clinical 
isolates (type a), Lane 5, 6, 8: P. aeruginosa clinical 
isolates (type b). 
 
None of the isolates tested were sensitive to all 
antibacterial agents. Multidrug-resistant (MDR) 
was defined as resistance to more than two 
antibiotic unrelated antibiotics. Twenty eight of 
73 isolates P. aeruginosa were resistant to all 
antibiotics. Of 73 isolates 59 (80.8%) were known 
as MDRPA isolates. The most frequent resistance 
profile among our isolates was included resistance 
to 6(38.4%), 4(27.4), 5(17.8%), 3(12.3%) and 
2(6.8%) antibiotics. Different pattern of multi- 
drug resistance in P. aeruginosa investigated in 
this study are summarized in table 2. Of 73 
clinical isolates of P. aeruginosa, 59 isolates 
(80.8%) had type a flagellin and 14 isolates 
(19.2%) had type b flagellin (Figure 1). 
 
DISCUSSION 
     P. aeruginosa is a serious nosocomial 
pathogen and major cause of fatal infections in 
cystic fibrosis, hospitalized, 
immunocompromised and especially burn patients 
[15, 16]. The main causes of mortality and 
morbidity in burn wound infections could be 
associated with drug resistance and lack of proper 
immune response [11]. The existence of multi 
drug resistance and its spreading among P. 
aeruginosa isolates lead to many problems 
concerning the treatment of such infections [4]. 
Therefore continuous surveillance in order to 
prevent the further spread of MDRPA isolates and 
also inhibition of colonization in burn centers 
should be employed. In our study the resistance 
rate of P. aeruginosa isolates to investigated 
antibiotics was relatively high. All isolates were 
absolutely resistant to tobramycin and 
ciprofloxacin. In compare to performed studies in 
Brazil, Turkey, Thailand, United State, China and 
Iran (2010 and 2012) a high resistance to 
tobramycin and ciprofloxacin were seen in our 
study [4, 6, 17-19]. The lowest resistance rates 
were seen against imipenem (64.4%) in compare 
with other tested antibiotics. Previous studies that 
were performed in Iran revealed different 
resistance rate to antibiotics used to treat burn 
wound infected by P. aeruginosa.  
For example, Rastegar et al In the Tohid Burn 
Center in Tehran showed that more than 95% of 
isolates were resistance to gentamicin, 
carbenicillin, co-trimoxazole, ceftizoxime and 
tetracycline while resistance to amikacin, and 
ciprofloxacin was 90% and 82% respectively 
[20]. In a study conducted by Moradian et al the 
rate of resistance to ciprofloxacin, ceftazidime, 
gentamicin, amikacin and imipenem was 38.9%, 
92.6%, 55.5%, 46.2% and 53.7% respectively 
[18]. Another study that was done by Hadadi et al 
showed that 75% of isolates were resistance to 
imipenem and 39% to ciprofloxacin [21].  
The most main factors that play crucial role in 
creating these differences may be as follows: 
Hygienic statement, difference in the type of 
strains, epidemiological conditions, unrestricted 
prescriptions of antibiotics for treatment of burn 
infections and ability of strains in acquisition of 
resistance genes [18, 22, 23]. 
Of 73 isolates 59 (80.8%) were multidrug 
resistant which is higher than rate of MDR 
reported in Turkey (20.9%) [19], Brazil(71%) 
[17], Iran(42.3%) [22] and lower than china 
(90.1%) [6](1-s) and Thailand (100%) [23]. 
Multidrug resistance in P aeruginosa is an 
increasing problem especially in developing 
countries [1]. The high frequency of MDRPA 
isolated from burn units has been confirmed by 
several investigators [1, 4]. Karlowsky et al. 
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in to 9.9% during three years [24]. Previous results 
in Iran showed a progressive increase in MDRPA 
from 5.46% [4] in 2009 to 45.3% [22] in 2013. In 
accordance with recent data unfortunately, the 
results of our study disclosed that the increase of 
multi drug resistance among P. aeruginosa 
isolated from Iranian burn patients has reached a 
critical point to the extent that for treatment of 
these infections must be recruited multiple drug 
regimens.  
Given the antibiotic failure in the treatment of 
infections caused by P. aeruginosa and need to 
multiple drug regimens, it appears that alternative 
ways such as immunity to prevent and treatment 
of these infections could be informative [25-27]. 
As previous mentioned, flagellin protein as a 
major virulence factor has important role of 
immunity against infections caused by MDRPA. 
According to the studies, more than 95 % of 
clinical isolates of P. aeruginosa are flagellated 
[28].  
Therefore it is important to know the frequency 
and type of flagellin. In our study all of isolates 
were positive for flagellin and type a flagellin was 
predominant. This results is in line with other 
studies [29, 30]. 
 
CONCLUSION  
      In summary, our results demonstrated high 
frequency of type a flagellin their important role 
as a major virulence factor in P. aeruginosa 
isolated from burn patients. Imipenem was the 
most effective drug in vitro assessment while 
tobramycin and ciprofloxacin could not be 
effective drugs for treatment of burn infections. 
High frequency of MDR among P. aeruginosa 
isolated from burn patients revealed the important 
role of indiscriminate and unregulated use of 
antibiotics as selective pressure for dissemination 
MDR in our region. However, functional 
surveillance is urgently needed to prevent 
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